MDxHealth prices $20M direct share offering at $0.454 per share
MDxHealth SA filed a prospectus supplement for a direct offering of 44.05 million ordinary shares at $0.454 each, expecting gross proceeds of about $20 million.
What happened
MDxHealth SA, a urologic diagnostics company, filed a prospectus supplement on August 13, 2026, for a direct offering of 44,052,862 ordinary shares. The shares are priced at $0.454 each, matching the last sale price on August 10, 2026. The offering is expected to close on or about August 13, 2026.
The company expects gross proceeds of approximately $20 million, before offering expenses of about $200,000. No underwriter or placement agent is involved; shares are sold directly to investors under a securities purchase agreement dated August 11, 2026.
On the event date, MDXH shares closed at $0.808, up 74.89% from the previous close of $0.462, with volume of 324 million shares versus an average of about 722,000.
The filing
The filing is a Form 424B5, which is a prospectus supplement used to finalize and detail a securities offering under an existing shelf registration. The company's earlier shelf registration (Form F-3, file number 333-292463) allowed it to offer shares over time without filing a new registration each time.
In this case, MDxHealth is selling ordinary shares directly to investors, meaning it bypasses the traditional underwriter process. The price per share was set at the market price on the day before the securities purchase agreement was signed.
The prospectus notes that MDxHealth qualifies as an 'emerging growth company' and is a 'foreign private issuer', which exempts it from certain disclosure and procedural requirements. The company also disclosed that in May 2026 it decided to discontinue its Resolve UTI offering and close its laboratory operations in Plano, Texas.
What this means
A shelf takedown is when a company that has already registered securities for future sale activates that registration to actually sell shares. Here, MDxHealth is issuing new ordinary shares, which increases the total number of shares outstanding. The direct sale without an underwriter means the company saves on underwriting fees but must find its own buyers.
The $0.454 per-share price is the market price at the time the agreement was signed, so the offering is not a discount to market. The company expects to receive about $20 million, which it will use for general corporate purposes (as described in the filing's 'Use of Proceeds' section).
The shares trade on the Nasdaq Capital Market under 'MDXH'. Because this is a new issuance of shares, current shareholders will see their ownership stake diluted. The sharp price increase and high volume on the event date suggest significant market activity, but the source does not explain why the price moved so dramatically, so no cause is assigned here.
Sources
- Daily price and volume history
- 424B5 filed 2026-08-13
Information summarized by AI from the sources listed above. May contain errors — informational only, not investment advice.